Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912091 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL11749582 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRMAPK1XDH | |
| SCHEMBL204939 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL8903476 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL202693 | 0.78 | ALDH1A1 (0.63) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL222175 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TSHRMAPK1XDH | |
| SCHEMBL7032612 | 0.78 | ALDH1A1 (0.63) | ALDH1A1CYP3A4TSHRMAPK1XDH | |
| SCHEMBL20535873 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL4695676 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRMAPK1PDE7A | |
| SCHEMBL4931946 | 0.77 | CCR6 (0.43) | ALDH1A1CYP3A4TSHRMAPK1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143752-A | Aminoquinoline derivative, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-9000028-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2013-09-12 | — | — | US | disclosed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996036588-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED AROMATIC AMINO COMPOUNDS | NOVARTIS AG (CH) | 1996-11-21 | — | — | WO | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5270309-A | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0303387-B1 | KYNURENIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1993-04-21 | — | — | EP | disclosed |
| EP-0303387-A1 | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
| US-4053527-A | REACTING HALONITROANILINES WITH ALCOHOLS AND NITROSATING AGENTS ION | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | ALDH1A1 1971/4885CYP3A4 1179/4885TSHR 3810/4885 |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | ALDH1A1 3181/4885CYP3A4 2591/4885TSHR 2517/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | ALDH1A1 3023/4885CYP3A4 2124/4885TSHR 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.